Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23708986 | 1.00 | HPGD (0.61) | HPGDALDH1A1TSHRHSD11B1SMN1; SMN2 | |
| SCHEMBL23708985 | 1.00 | HPGD (0.61) | HPGDALDH1A1TSHRHSD11B1SMN1; SMN2 | |
| SCHEMBL22138338 | 0.98 | HPGD (0.58) | HPGDALDH1A1TSHRHSD11B1SMN1; SMN2 | |
| SCHEMBL25576093 | 0.93 | HPGD (0.52) | HPGDALDH1A1TSHRHSD11B1SMN1; SMN2 | |
| SCHEMBL2686662 | 0.83 | HPGD (0.63) | HPGDALDH1A1TSHRHSD11B1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL30398430 | 0.83 | HPGD (0.57) | HPGDALDH1A1TSHRHSD11B1SMN1; SMN2 | |
| SCHEMBL12856491 | 0.81 | HPGD (0.79) | HPGDALDH1A1TSHRHSD11B1SMN1; SMN2 | |
| SCHEMBL8518585 | 0.81 | HPGD (0.79) | HPGDALDH1A1TSHRHSD11B1SMN1; SMN2 | |
| SCHEMBL31389558 | 0.80 | HPGD (0.64) | HPGDALDH1A1TSHRHSD11B1SMN1; SMN2 | |
| SCHEMBL15075709 | 0.79 | HTT (0.55) | HPGDALDH1A1TSHRHSD11B1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11077101-B1 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-2252611-A1 | (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | N.V. Organon (NL) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009098283-A1 | (DIHYDRO)PYRROLO[2,1-A]ISOQUINOLINES | N.V. ORGANON (NL) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11986471-B2 | Compounds and methods of use | XDH, F12, LPXN | HPGD 1329/4885ALDH1A1 223/4885TSHR 1920/4885 |
| US-11077101-B1 | Compounds and methods of use | XDH, F12, LPXN | HPGD 1329/4885ALDH1A1 223/4885TSHR 1920/4885 |
| US-20230060499-A1 | COMPOUNDS AND METHODS OF USE | XDH, F12, LPXN | HPGD 1329/4885ALDH1A1 223/4885TSHR 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.